Skip to content

Children With Aluminium Contact Allergy: Cutaneous Exposure Study

Children With Aluminium Contact Allergy: Cutaneous Exposure Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04438135
Enrollment
15
Registered
2020-06-18
Start date
2020-06-10
Completion date
2022-04-07
Last updated
2022-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aluminum Allergy, Contact Allergy, Contact Dermatitis

Keywords

vaccination granuloma, aluminium contact allergy, children, contact dermatitis, repeated open application test, patch test

Brief summary

Aluminium is used in many different cosmetic products, including make-up, deodorants and sunscreen. The purpose of this study is to investigate whether these everyday skin products with small amounts of aluminium can cause skin reactions in children diagnosed with contact allergy to aluminium. The study is conducted as a Repeated Open Application Test study (ROAT), a method originally developed to clarify the clinical relevance of questionable and positive patch samples, by imitating everyday use of a skin product.

Detailed description

The study is conducted as a Repeated Open Application Test study (ROAT), a method originally developed to clarify the clinical relevance of questionable and positive patch samples, by imitating everyday use of a skin product. The skin products will consist of ordinary sunscreens with and without aluminium, with colour code red and blue, respectively (masked for both investigator and participants). At the beginning of the trial, the study participants will be given the two creams. On the lower back of the children, two areas each 10 cm2 are marked with red and blue, respectively. In each area, sunscreen corresponding to the generally recommended amounts must be applied twice a day. The children should be seen on day 0 for interviews and objective examination. They must then be seen again on day 7 and day 14. On day 14 of the ROAT, a patch test is made to validate the results of the ROAT study. The study is scheduled to last for a maximum of 21 days with 4-5 consultations per child. If there is a skin reaction in connection with the ROAT study before the 14 days have elapsed, the study will end and a patch test will be performed.

Interventions

OTHERRepeated open application test

parallel application of two different types of lotion with and without aluminium.

Sponsors

National Allergy Research Center, Denmark
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

Repeated Open Application test

Eligibility

Sex/Gender
ALL
Age
2 Years to 10 Years
Healthy volunteers
No

Inclusion criteria

* Children with contact allergies to aluminium, demonstrated by patch tests at the Skin and Allergy Department, Gentofte Hospital and thus registered in the Clinical Database for Contact Allergy. * Activity (itching) of the granulom within the last six months * Written consent obtained from all custodians. * Self-assessed worsening of skin symptoms after contact with aluminium-containing sunscreens.

Exclusion criteria

* Treatment with systemic steroid preparations within 1 week. * Treatment with topical steroid preparations at or near the test area within 1 week. * Treatment with systemic immune suppression. * Treatment with antibiotics within 1 week. * If the children become ill during the study, they should contact the project manager who will clinically assess the child and evaluate whether the child can continue to participate in the study or should be excluded due to the possibility of misinterpretation of any rash. * Active eczema or other skin symptoms on the tested area

Design outcomes

Primary

MeasureTime frameDescription
positive testtwo weeksAfter two weeks of daily application, both test sites on all children will be evaluated and scored according to ROAT guidelines. The ROAT will be considered positive at a score of 5 points or more. Photographs will be taken of all reactions (positive and negative) for documentation.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026